fig1

Figure 1. Cancer-immunity cell cycle (modified from^[22]). In a first step, neoantigens are released by cancer cells (1). These neoantigens are then absorbed by dendritic cells (DC). Subsequently, DCs present the antigens to the T cells on major histocompatibility Complex (MHC) I and MHC II molecules (2). This leads to activation of T-cell responses against cancer-specific antigens (3) that are considered foreign or for which central tolerance is incomplete. The activated T cells are then transported into the tumor bed (4) where they infiltrate the tumor (5). Once there, the T cells can specifically recognize (6) and destroy (7) cancer cells through the interaction between their T cell receptor (TCR) and the tumor-specific antigens bound to MHC I. The destruction of the cancer cells releases additional tumor-associated antigens (1), which in turn strengthens the immune response.